Full text is available at the source.
The lancet. Diabetes & endocrinology···
Semaglutide's effects on heart failure with preserved pumping and type 2 diabetes in obesity, varying by starting blood sugar levels
Updated
Abstract
In a trial with 616 participants, semaglutide 2·4 mg led to a mean difference of 6·7 points in heart failure-related symptoms compared to placebo after 52 weeks.
- Improvements in heart failure-related symptoms, measured by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, were observed across different baseline blood sugar levels.
- Participants receiving semaglutide experienced significant reductions in body weight compared to those on placebo, regardless of their initial blood sugar levels.
- Hypoglycaemia events were lower in the semaglutide group (10%) compared to the placebo group (7%), suggesting better safety profiles.
- The results indicate that semaglutide may provide benefits for heart failure symptoms and weight loss in patients with obesity-related heart failure and type 2 diabetes.
Simplified
BACKGROUND: About half of patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) have type 2 diabetes. In the STEP-HFpEF DM trial of adults with obesity-related HFpEF and type 2 diabetes, subcutaneous once weekly semaglutide 2·4 mg conferred improvements in heart failure-related symptoms and physical limitations, bodyweight, and other heart failure outcomes. We aimed to determine whether these effects of semaglutide differ according to baseline HbA. 1c
METHODS: STEP-HFpEF DM, a double-blind, randomised, placebo-controlled trial conducted at 108 clinical research sites across 16 countries in Asia, Europe, and North and South America, included individuals aged 18 years or older with documented HFpEF (left ventricular ejection fraction ≥45%), type 2 diabetes, and obesity (BMI ≥30 kg/m). Participants were randomly assigned (1:1), with a block size of four within each stratum using an interactive web response system, stratified by baseline BMI (<35 kg/mvs ≥35 kg/m), to receive either semaglutide 2·4 mg or placebo subcutaneously. The effects of semaglutide versus placebo on the efficacy endpoints were evaluated by HbAcategories at baseline: low (<6·5%; <48 mmol/mol), medium (6·5% to <7·5%; 48 mmol/mol to <58 mmol/mol), and high (≥7·5%; ≥58 mmol/mol). The dual primary endpoints were change in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and bodyweight percentage from baseline to 52 weeks and were assessed in all randomly assigned participants by intention to treat. Hypoglycaemia events were also analysed to assess safety in all randomly assigned participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT04916470. 2 2 2 1c
FINDINGS: Between June 27, 2021 and Sept 2, 2022, 616 participants were enrolled and randomly assigned (mean age 68·4 years [SD 8·9]; 273 [44%] were female, 343 [56%] were male, and 519 [84%] were White). The low baseline HbAgroup included 227 participants (112 assigned to semaglutide and 115 to placebo), the medium baseline HbAgroup included 226 participants (124 assigned to semaglutide and 102 to placebo), and the high baseline HbAgroup included 163 participants (74 assigned to semaglutide and 89 to placebo). The median duration of follow-up in the overall trial was 401 days (IQR 400-405). The change in KCCQ-CSS from baseline to 52 weeks was 12·4 points (95% CI 8·8 to 16·0) with semaglutide versus 5·7 points (2·1 to 9·2) with placebo (mean difference 6·7 points [1·6 to 11·8]) in the low baseline HbAgroup, 14·5 points (11·0 to 17·9) versus 8·5 points (4·8 to 12·2; 6·0 points [0·9 to 11·1]) in the medium baseline HbAgroup, and 14·5 points (10·0 to 19·0) versus 4·8 points (0·7 to 8·9; 9·6 points [3·5 to 15·7]) in the high baseline HbAgroup (p=0·64; p=0·46). The change in bodyweight percentage from baseline to 52 weeks was -10·8 (95% CI -12·1 to -9·5) with semaglutide versus -3·3% (-4·6 to -2·0) with placebo (mean difference -7·5% [-9·4 to -5·6]) in the low baseline HbAgroup, -9·6% (-10·8 to -8·3) versus -3·3% (-4·7 to -1·9; -6·3 [-8·2 to -4·4]) in the medium baseline HbAgroup, and -8·6% (-10·2 to -7·0) versus -3·6% (-5·2 to -2·1; -5·0 [-7·2 to -2·7]) in the high baseline HbAgroup (p=0·22; p=0·083). Hypoglycaemia events occurred in 30 (10%) of 310 participants (70 events; 22·9 events per 100 person-years) in the semaglutide group compared with 21 (7%) of 306 participants in the placebo group (90 events; 29·5 events per 100 person-years). 1c1c1c1c1c1c interaction trend1c1c1c interaction trend
INTERPRETATION: Semaglutide 2·4 mg improved heart failure-related symptoms and physical limitations, and reduced bodyweight in patients with obesity-related HFpEF and type 2 diabetes, all independently of baseline HbA, and resulted in lower rates of hypoglycaemia than placebo, despite a well controlled baseline HbAand broad use of concomitant glucose-lowering medications. 1c1c
FUNDING: Novo Nordisk.
Related papers
Apr '24
Semaglutide compared to placebo in people with obesity-related heart failure with normal pumping function: combined analysis of two clinical trials
top 1% journal
cited by 306 papers
randomized controlled trial
Sep '24
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Normal Pumping Function
top 1% journal
cited by 32 papers
randomized controlled trial
Jun '24
Semaglutide and Heart Failure Severity in Obesity-Related Heart Failure with Normal Pumping Function
top 1% journal
cited by 46 papers
randomized controlled trial
Jun '24
Semaglutide’s effects on obesity-related heart failure with preserved pumping function vary by sex
top 1% journal
cited by 44 papers
randomized controlled trial
Sep '24
Semaglutide compared to placebo in heart failure patients with mildly reduced or preserved heart pumping function: combined analysis of four clinical trials
top 1% journal
cited by 230 papers
randomized controlled trial
Oct '25
Semaglutide and exercise effects on heart function in obesity-related heart failure with preserved pumping ability
top 1% journal
cited by 5 papers
randomized controlled trial
Sep '24
Inflammation in Obesity-Related Heart Failure with Preserved Pumping Strength
top 1% journal
cited by 69 papers
randomized controlled trial
Jan '17
Effectiveness and safety of once-weekly semaglutide alone compared to placebo in people with type 2 diabetes
top 1% journal
cited by 636 papers
randomized controlled trial
Aug '24
Semaglutide and heart health in people with obesity and existing heart failure: results from the SELECT trial
top 1% journal
cited by 189 papers
randomized controlled trial
Mar '21
Weekly Semaglutide 2.4 mg for Adults with Overweight or Obesity and Type 2 Diabetes: A Controlled Clinical Trial
top 1% journal
cited by 1,112 papers
randomized controlled trial